Suppr超能文献

基因预测血压、抗高血压药物与心力衰竭风险:一项孟德尔随机化研究

Genetically predicted blood pressure, antihypertensive drugs and risk of heart failure: a Mendelian randomization study.

作者信息

Lian Jiao, Shi Xuezhong, Jia Xiaocan, Fan Jingwen, Wang Yuping, Zhao Yang, Yang Yongli

机构信息

Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, PR China.

出版信息

J Hypertens. 2023 Jan 1;41(1):44-50. doi: 10.1097/HJH.0000000000003297. Epub 2022 Sep 13.

Abstract

BACKGROUND

Elevated blood pressure (BP) was associated with higher risk of heart failure, but the relationship between BP-lowering via antihypertensive drugs and diminution of heart failure was inconclusive. This study aimed to estimate the causal association of BP with heart failure, and explore the effects of BP-lowering through different antihypertensive drug classes on heart failure risk using Mendelian randomization analysis with genetic variants as instrument variables.

METHODS

Genetic variants associated with BP were derived from UK Biobank ( n  = 317 754) and the genome-wide association study (GWAS) meta-analysis of UK Biobank and International Consortium of Blood Pressure ( n  = 757 601). Heart failure summary association data were contributed by HERMES Consortium (47 309 heart failure cases and 930 014 controls). Inverse variance weighted (IVW) was performed to estimate causality between exposure and outcome, and weighted median was utilized as sensitivity analysis, and Mendelian randomization-Egger regression was used to identify pleiotropy of instrument variables. Multivariable Mendelian randomization (MVMR) was applied to control for the confounders.

RESULTS

Genetically predicted SBP and DBP were associated with heart failure [SBP: odds ratio (OR) = 1.355, 95% confidence interval (CI) 1.201-1.529; DBP: OR = 1.348, 95% CI 1.213-1.498] in UK Biobank. Likewise, in the GWAS meta-analysis of UK Biobank and International Consortium of Blood Pressure, the causal associations were observed between SBP, DBP and heart failure (SBP: OR = 1.237, 95% CI 1.188-1.289; DBP: OR = 1.337, 95% CI 1.245-1.437). Genetically determined β-blockers and calcium channel blockers (CCBs) were associated with lower risk of heart failure (β-blockers: OR = 0.617, 95% CI 0.453-0.839; CCBs: OR = 0.730, 95% CI 0.625-0.851). No association was found between angiotensin receptor blockers (ARBs) and heart failure (OR = 1.593, 95% CI 0.647-3.924). When adjusted for smoking, alcohol, physical activity, fruit and vegetable intake, the results were stable.

CONCLUSION

Our study indicates causal associations between SBP, DBP, and heart failure, and suggests the preventive effects of heart failure by BP-lowering using β-blockers and CCBs.

摘要

背景

血压升高与心力衰竭风险增加相关,但通过降压药物降低血压与心力衰竭减轻之间的关系尚无定论。本研究旨在评估血压与心力衰竭之间的因果关联,并使用以基因变异为工具变量的孟德尔随机化分析,探讨不同类别降压药物降低血压对心力衰竭风险的影响。

方法

与血压相关的基因变异来自英国生物银行(n = 317754)以及英国生物银行和国际血压联盟的全基因组关联研究(GWAS)荟萃分析(n = 757601)。心力衰竭汇总关联数据由HERMES联盟提供(47309例心力衰竭病例和930014例对照)。采用逆方差加权(IVW)来估计暴露与结局之间的因果关系,并使用加权中位数进行敏感性分析,同时采用孟德尔随机化-伊格回归来识别工具变量的多效性。应用多变量孟德尔随机化(MVMR)来控制混杂因素。

结果

在英国生物银行中,基因预测的收缩压和舒张压与心力衰竭相关[SBP:比值比(OR)= 1.355,95%置信区间(CI)1.201 - 1.529;DBP:OR = 1.348,95% CI 1.213 - 1.498]。同样,在英国生物银行和国际血压联盟的GWAS荟萃分析中,观察到收缩压、舒张压与心力衰竭之间存在因果关联(SBP:OR = 1.237,95% CI 1.188 - 1.289;DBP:OR = 1.337,95% CI 1.245 - 1.437)。基因决定的β受体阻滞剂和钙通道阻滞剂(CCB)与较低的心力衰竭风险相关(β受体阻滞剂:OR = 0.617,95% CI 0.453 - 0.839;CCB:OR = 0.730,95% CI 0.625 - 0.851)。未发现血管紧张素受体阻滞剂(ARB)与心力衰竭之间存在关联(OR = 1.593,95% CI 0.647 - 3.924)。在对吸烟、饮酒、体育活动、水果和蔬菜摄入量进行调整后,结果依然稳定。

结论

我们的研究表明收缩压、舒张压与心力衰竭之间存在因果关联,并提示使用β受体阻滞剂和CCB降低血压对心力衰竭具有预防作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验